Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 5, 1996, Pages 459-464

  Pectasides, D ^a   Pavlidis, N ^b   Gogou, L ^a   Antoniou, F ^a   Nicolaides, C ^b   Tsikalakis, D ^a   Fountzilas, G ^c  

^a METAXA CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Breast cancer; CA 15 3, Carcinoembryonic antigen; Follow up; Mucin like carcinoma associated antigen; Tumor polypeptide antigen

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN LIKE CARCINOMA ASSOCIATED ANTIGEN; POLYPEPTIDE; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PATIENT MONITORING; POSTOPERATIVE PERIOD;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0029831450     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199610000-00007     Document Type: Article

References (24)

1. Steward DM, Nixon D, Zameheek N, Aisemberg A. Carcinoembryonic antigen in breast carcinoma patients: serial levels and disease progression. Cancer 1974;33:1246-52.
2. Martin EW, Kibbey WE, Di Vecchia L. Carcinoembryonic antigen: clinical and historical aspects. Cancer 1976;37:62.
3. Jotti GS, Bombardieri E. Circulating tumour markers in breast cancer. Anticancer Res 1990;10:253-8.
4. Nicolini A, Capri AD, Marco G, Giulani L, Giordani R, Palla S. A rational postoperative follow-up with CEA, TPA and urinary hydroxyproline in breast cancer patients. Cancer 1989;63:2037-46.
5. Barak M, Steiner M, Finkel B, Abrahamson J, Antal S, Gruener N. CA 15-3, TPA and MCA as markers for breast cancer. Eur J Cancer 1990;26:577-80.
6. Hilkens J, Buijs F, Hilgers J, et al. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 1984;34:197-206.
7. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984;3:223-32.
8. Tobias R, Rothwell C, Wagner J, Green A, Liu YSK. Development and evaluation of radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D8/DF3. J Am Assoc Clin Chem 1985;31:986.
9. Haves DF, Zurawski VR, Kufe DW. Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986;4:1542-50.
10. Colomer R, Lianes P, Ruibal A, Cortes-Funes H, Salvador L, Hornedo J. Circulating CA 15-3 levels in patient with breast cancer predict relapse and correlate with metastatic tumor burden [Abstract]. Proc Am Soc Clin Oncol 1988;7:20.
11. Stahli C, Caravatti M, Takacs B, Staehelin T, Carmann H. A mucinous carcinoma associated antigen (MCA) defined by three monoclonal antibodies against different epitopes. Cancer Res 1988;48:6799-802.
12. Miserez AR, Gunes I, Muller-Brand J, Walther E, Fridrich R, Macke H. Clinical value of a mucin-like carcinoma associated antigen in monitoring breast cancer patients in comparison with CA 15-3. Eur J Cancer 1991;27:126-31.
13. Gion G, Plebani M, Mione R, Penzo L, Meo S, Burlina A. Serum CA 549 in primary breast cancer: comparison with CA 15-3 and MCA. Br J Cancer 1994;69:721-5.
14. Ciatto S, Rosselli Del Turco M, et al. Early detection of breast cancer recurrences through periodic follow-up: is it useless? Tumori 1985;71:325-9.
15. Zwavelling A, Albers GH, Felthuis W, Herman J. An evaluation of routine follow-up for detection of breast cancer recurrences. J Surg Oncol 1987;34:194-200.
16. Stierer M, Rosen HR. Influence of early diagnosis on prognosis of recurrent breast cancer. Cancer 1989;64:1128-31.
17. Colomer R, Ruibal A, Genolla J, et al. Circulating CA 15-3 levels in the post-surgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989;13:123-33.
18. Buck I, Lindner C, Boge K, Kitschke HJ. Zur Wertig-Keit der tumor marker CA 15-3 and CEA beim Mamakarzinon. Arch Gynecol Obstet 1989;245:674-7.
19. Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 1989;64:1674-81.
20. Pons-Aniset DMF, Krebs BP, Mira R, Namer M. Value of CA 15-3 in the follow-up of breast cancer patients. Br J Cancer 1987;55:567-9.
21. De Wit R, Hoek FJ, Bakker PJ, Veenhof CH. A comparison of CA 549 with CA 15-3 and MCA in patients with metastatic breast cancer. Ann Oncol 1992;3:314-5.
22. Kallioniemi DP, Oksa HJ, Aaran RK, Hietanen T, Lehtinen M, Koivula T. Serum CA 15-3 assay in the diagnosis and follow-up of breast cancer. Br J Cancer 1988;58:213-5.
23. Bombardieri E, Pizzichetta M, Veronesi P, et al. CA 15-3 determination in patients with breast cancer: clinical utility for the detection of distant metastases. Eur J Cancer 1993;29:144-6.
24. Caponigro F, Iaffaioli RV, Pagliarulo C, et al. CA 15-3 in human breast cancer: comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Int J Biol Markers 1990;5:73-6.